Improving the Preclinical Mouse Efficacy Studies of Adenomyosis

The development of specific therapeutics for patients with adenomyosis is a pressing unmet need. Yet no novel compounds are currently undergoing clinical evaluation. This may be attributable to our limited understanding of the pathophysiology of adenomyosis. Many methodological deficiencies in animal studies are an important cause of translational failure. Systematic review of published preclinical mouse efficacy studies of adenomyosis demonstrates the need for greater attention to rigorous methodology. Besides standard quality criteria that apply to all animal studies, there are issues that are specific to adenomyosis. Addressing these can improve the value of preclinical mouse efficacy studies in translational research. This chapter considers ways of improving mouse efficacy studies of adenomyosis and highlights areas where more research is needed. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others

Wood C. Surgical and medical treatment of adenomyosis. Hum Reprod Update. 1998;4:323–36. Badawy AM, Elnashar AM, Mosbah AA. Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial. Acta Obstet Gynecol Scand. 2012;91:489–95. Ota H, Igarashi S, Hatazawa J, Tanaka T. Is adenomyosis an immune disease? Hum Reprod Update. 1998;4:360–7. Maia Jr H, Casoy J, Correia T, Freitas L, Pimentel K, Athayde C, et al. Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis. Gynecol Endocrinol. 2006;22:547–51. Arrowsmith J. A decade of change. Nat Rev Drug Discov. 2012;11:17–8. Guo SW, Evers JL. Lack of transparency of clinical trials on endometriosis. Obstet Gynecol. 2013;121:1281–90. Guo SW, Hummelshoj L, Olive DL, Bulun SE, D’Hooghe TM, Evers JL. A call for more transparency of registered clinical trials on endometriosis. Hum Reprod. 2009;24:1247–54. Guo SW. An overview of the current status of clinical trials on endometriosis: issues and concerns. Fertil Steril. 2013;101:183–90.e4. Martic-Kehl MI, Schibli R, Schubiger PA. Can animal data predict human outcome? Problems and pitfalls of translational animal research. Eur J Nucl Med Mol Imaging. 2012;39:1492–6. Unger EF. All is not well in the world of translational research. J Am Coll Cardiol. 2007;50:738–40. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6:114–8. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJ. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res. 2007;74:343–55. Couzin-Frankel J. When mice mislead. Science. 2013;342:922–3, 5. van der Worp HB, Macleod MR. Preclinical studies of human disease: time to take methodological quality seriously. J Mol Cell Cardiol. 2011;51:449–50. Collins FS, Tabak LA. Policy: NIH plans to enhance reproducibility. Nature. 2014;505:612–3. Perrin S. Preclinical research: make mouse studies work. Nature. 2014;507:423–5. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187–91. Guo SW. Methodological issues in preclinical mouse efficacy studies of adenomyosis. Curr Obstet Gynecol Rep. 2012;1:138–45. Greaves P, White IN. Experimental adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20:503–10. Mori T, Nagasawa H, Takahashi S. The induction of adenomyosis in mice by intrauterine pituitary isografts. Life Sci. 1981;29:1277–82. Zhang X, Yuan H, Deng L, Hu F, Ma J, Lin J. Evaluation of the efficacy of a danazol-loaded intrauterine contraceptive device on adenomyosis in an ICR mouse model. Hum Reprod. 2008;23:2024–30. Green AR, Styles JA, Parrott EL, Gray D, Edwards RE, Smith AG, et al. Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer. Exp Toxicol Pathol. 2005;56:255–63. Parrott E, Butterworth M, Green A, White IN, Greaves P. Adenomyosis – a result of disordered stromal differentiation. Am J Pathol. 2001;159:623–30. Liu X, Guo SW. Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis. J Obstet Gynaecol Res. 2011;37:696–708. Guttner J. Adenomyosis in mice. Z Versuchstierkd. 1980;22:249–51. Ostrander PL, Mills KT, Bern HA. Long-term responses of the mouse uterus to neonatal diethylstilbestrol treatment and to later sex hormone exposure. J Natl Cancer Inst. 1985;74:121–35. Mori T, Yamasaki S, Masui F, Matsuda M, Sasabe H, Zhou YF. Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp Biol Med (Maywood). 2001;226:429–33. Mehasseb MK, Bell SC, Habiba MA. The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse. Reproduction. 2009;138:341–50. Mori T, Nagasawa H. Mechanisms of development of prolactin-induced adenomyosis in mice. Acta Anat (Basel). 1983;116:46–54. Mori T, Ohta Y, Nagasawa H. Ultrastructural changes in uterine myometrium of mice with experimentally-induced adenomyosis. Experientia. 1984;40:1385–7. Mori T, Nagasawa H, Nakajima Y. Strain-difference in the induction of adenomyosis by intrauterine pituitary grafting in mice. Lab Anim Sci. 1982;32:40–1. Mehasseb MK, Bell SC, Habiba MA. Neonatal administration of tamoxifen causes disruption of myometrial development but not adenomyosis in the C57/BL6J mouse. Reproduction. 2010;139:1067–75. Razvi N, Greaves P, Styles J, Edwards R, White IN. Absence of uterine tumours in CD-1 mice treated neonatally with subcutaneous tamoxifen or 4-hydroxyoestradiol. Exp Toxicol Pathol. 2007;59:177–85. Zhou YF, Matsuda M, Mori T, Sakamoto S, Mitamura T. Effects of mifepristone (RU486) treatment on the development of uterine adenomyosis induced by pituitary grafting in mice. Life Sci. 2000;67:2713–20. Mori T, Kawashima S, Nagasawa H. Induction of uterine adenomyosis by pituitary grafting and retardation of its development by bromocriptine-mesilate (CB-154) in BALB/c mice. In Vivo. 1991;5:107–9. Zhou YF, Mori T, Kudo H, Asakai R, Sassa S, Sakamoto S. Effects of angiogenesis inhibitor TNP-470 on the development of uterine adenomyosis in mice. Fertil Steril. 2003;80 Suppl 2:788–94. Zhou YF, Mori T, Nagasawa H, Nakayama T, Kubota T, Sakamoto S. Probucol, a hypocholesterolemic agent, prevents the development of uterine adenomyosis induced by pituitary grafting in mice. Anticancer Res. 2004;24:2209–12. Mao X, Wang Y, Carter AV, Zhen X, Guo SW. The retardation of myometrial infiltration, reduction of uterine contractility, and alleviation of generalized hyperalgesia in mice with induced adenomyosis by levo-tetrahydropalmatine (l-THP) and andrographolide. Reprod Sci. 2011;18:1025–37. Negus SS, Bilsky EJ, Do Carmo GP, Stevenson GW. Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia. Methods Mol Biol. 2010;617:79–91. Stevenson GW, Bilsky EJ, Negus SS. Targeting pain-suppressed behaviors in preclinical assays of pain and analgesia: effects of morphine on acetic acid-suppressed feeding in C57BL/6J mice. J Pain. 2006;7:408–16. Peric H, Fraser IS. The symptomatology of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20:547–55. Fraser IS. Mysteries of endometriosis pain: Chien-Tien Hsu Memorial Lecture 2009. J Obstet Gynaecol Res. 2010;36:1–10. Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain. 2006;10:77–88. He W, Liu X, Zhang Y, Guo SW. Generalized hyperalgesia in women with endometriosis and its resolution following a successful surgery. Reprod Sci. 2010;17:1099–111. Zhao T, Liu X, Zhen X, Guo SW. Levo-tetrahydropalmatine retards the growth of ectopic endometrial implants and alleviates generalized hyperalgesia in experimentally induced endometriosis in rats. Reprod Sci. 2011;18:28–45. Bannon AW, Malmberg AB. Models of nociception: hot-plate, tail-flick, and formalin tests in rodents. Curr Protoc Neurosci. 2007;Chapter 8:Unit 8 9. Vierck CJ. Animal models of pain. In: McMahon S, Koltzenburg M, editors. Wall and Melzack’s textbook of pain. Philadelphia: Elsevier; 2006. p. 175–85. Berkley KJ, Cason A, Jacobs H, Bradshaw H, Wood E. Vaginal hyperalgesia in a rat model of endometriosis. Neurosci Lett. 2001;306:185–8. Sengupta JN. Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol. 2009;194:31–74. Backonja MM, Stacey B. Neuropathic pain symptoms relative to overall pain rating. J Pain. 2004;5:491–7. Calvino B, Besson JM, Boehrer A, Depaulis A. Ultrasonic vocalization (22–28 kHz) in a model of chronic pain, the arthritic rat: effects of analgesic drugs. Neuroreport. 1996;7:581–4. Jourdan D, Ardid D, Eschalier A. Analysis of ultrasonic vocalisation does not allow chronic pain to be evaluated in rats. Pain. 2002;95:165–73. Wallace VC, Norbury TA, Rice AS. Ultrasound vocalisation by rodents does not correlate with behavioural measures of persistent pain. Eur J Pain. 2005;9:445–52. Langford DJ, Bailey AL, Chanda ML, Clarke SE, Drummond TE, Echols S, et al. Coding of facial expressions of pain in the laboratory mouse. Nat Methods. 2010;7:447–9. Sotocinal SG, Sorge RE, Zaloum A, Tuttle AH, Martin LJ, Wieskopf JS, et al. The Rat Grimace Scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. Mol Pain. 2011;7:55. Kunz G, Beil D, Huppert P, Noe M, Kissler S, Leyendecker G. Adenomyosis in endometriosis – prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod. 2005;20:2309–16. Taran FA, Wallwiener M, Kabashi D, Rothmund R, Rall K, Kraemer B, et al. Clinical characteristics indicating adenomyosis at the time of hysterectomy: a retrospective study in 291 patients. Arch Gynecol Obstet. 2011;285:1571–6. Benson RC, Sneeden VD. Adenomyosis: a reappraisal of symptomatology. Am J Obstet Gynecol. 1958;76:1044–57; discussion 57–61. Hadfield R, Mardon H, Barlow D, Kennedy S. Delay in the diagnosis of endometriosis: a survey of women from the USA and the UK. Hum Reprod. 1996;11:878–80. Husby GK, Haugen RS, Moen MH. Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand. 2003;82:649–53. Arruda MS, Petta CA, Abrao MS, Benetti-Pinto CL. Time elapsed from onset of symptoms to diagnosis of endometriosis in a cohort study of Brazilian women. Hum Reprod. 2003;18:756–9. Matsuzaki S, Canis M, Pouly JL, Rabischong B, Botchorishvili R, Mage G. Relationship between delay of surgical diagnosis and severity of disease in patients with symptomatic deep infiltrating endometriosis. Fertil Steril. 2006;86:1314–6; discussion 7. Parker JD, Leondires M, Sinaii N, Premkumar A, Nieman LK, Stratton P. Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis. Fertil Steril. 2006;86:711–5. Ferrero S, Bogliolo S, Rossi UG, Baldi C, Valenzano Menada M, Ragni N, et al. Unusual complication of excision of pelvic endometriosis: pseudoaneurysm of the left uterine artery. Fertil Steril. 2009;93:264–6. Kissler S, Zangos S, Kohl J, Wiegratz I, Rody A, Gatje R, et al. Duration of dysmenorrhoea and extent of adenomyosis visualised by magnetic resonance imaging. Eur J Obstet Gynecol Reprod Biol. 2008;137:204–9. Wood C. Adenomyosis: difficult to diagnose, and difficult to treat. Diagn Ther Endosc. 2001;7:89–95. Meredith SM, Sanchez-Ramos L, Kaunitz AM. Diagnostic accuracy of transvaginal sonography for the diagnosis of adenomyosis: systematic review and metaanalysis. Am J Obstet Gynecol. 2009;201:107.e1–6. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8, e1000412. Singtripop T, Mori T, Park MK, Sakamoto S, Kawashima S. Development of uterine adenomyosis after treatment with dopamine antagonists in mice. Life Sci. 1991;49:201–6. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, et al. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron. 1997;19:103–13. Chen Y, Zhu B, Zhang H, Liu X, Guo SW. Epigallocatechin-3-Gallate Reduces Myometrial Infiltration, Uterine Hyperactivity, and Stress Levels and Alleviates Generalized Hyperalgesia in Mice Induced With Adenomyosis. Reprod Sci. 2013;20:1478–91. Zhou YF, Mori T, Nagasawa H, Nakayama T, Kubota T, Sakamoto S. Probucol, a hypocholesterolemic agent, prevents the development of uterine adenomyosis induced by pituitary grafting in mice. Anticancer Res 2004;24:2209–12. Acknowledgment S-W G was supported in part by grants 81270676 and 81471434 from the National Science Foundation of China. Conflict of Interest Statement None declared. Author information Authors and Affiliations Corresponding author Editor information Editors and Affiliations Rights and permissions Copyright information © 2016 Springer International Publishing Switzerland About this chapter Cite this chapter Guo, SW., Habiba, M. (2016). Improving the Preclinical Mouse Efficacy Studies of Adenomyosis. In: Habiba, M., Benagiano, G. (eds) Uterine Adenomyosis. Springer, Cham. https://doi.org/10.1007/978-3-319-13012-5_8 Download citation DOI: https://doi.org/10.1007/978-3-319-13012-5_8 Published: Publisher Name: Springer, Cham Print ISBN: 978-3-319-13011-8 Online ISBN: 978-3-319-13012-5 eBook Packages: MedicineMedicine (R0)